BIO-key International (BKYI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
16 Mar, 2026Executive summary
A special meeting is scheduled for April 20, 2026, to vote on a reverse stock split amendment to the Certificate of Incorporation, with a split ratio between 1-for-2 and 1-for-10, at the Board's discretion, to be implemented by May 6, 2026 if approved.
The reverse split aims to help regain compliance with Nasdaq's $1.00 minimum bid price requirement and improve the marketability and liquidity of the stock.
All shareholders will be affected uniformly, with no dilution of ownership percentage except for minor adjustments due to fractional shares.
The Board recommends voting in favor of the proposal and retains the right to abandon or delay the split if deemed not in the best interest of the company.
Forward-looking statements highlight risks, including market conditions, compliance, and business uncertainties.
Voting matters and shareholder proposals
The sole proposal is to approve an amendment for a reverse stock split at a ratio between 1-for-2 and 1-for-10, with the final ratio and timing determined by the Board.
Approval requires more votes cast for than against; abstentions and broker non-votes will have no effect.
The Board unanimously recommends a vote "FOR" the proposal.
Only shareholders of record as of March 9, 2026, are entitled to vote.
Board of directors and corporate governance
The Board has full discretion to determine the split ratio and timing, or to abandon the split even after shareholder approval.
The Board is not responding to any takeover attempt and does not intend the split as an anti-takeover measure.
Latest events from BIO-key International
- Vote on a reverse stock split to regain Nasdaq compliance and enhance stock marketability.BKYI
Proxy Filing6 Mar 2026 - Q1 2024 revenue up 19.5% sequentially, gross margin 86%, net loss narrowed, cash flow positive.BKYI
Q1 20243 Feb 2026 - Q2 revenue fell, but margins improved and new products, AWS entry, and financing support outlook.BKYI
Q2 20241 Feb 2026 - Q3 2024 revenue up 18%, net loss narrowed, but going concern risks remain.BKYI
Q3 202414 Jan 2026 - 2024 net loss cut nearly in half as shift to high-margin software and key partnerships drive gains.BKYI
Q4 202426 Dec 2025 - Shareholders to vote on directors, auditor, and executive pay, with annual say-on-pay recommended.BKYI
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, executive pay, and equity plan amendments.BKYI
Proxy Filing1 Dec 2025 - Resale of 2M+ shares supports growth in IAM, but poses dilution and market risks.BKYI
Registration Filing28 Nov 2025 - IAM SaaS firm registers 3.1M-share resale; proceeds from warrants to fund operations and debt.BKYI
Registration Filing28 Nov 2025